US Patent

US9248123 — Methods of providing weight loss therapy in patients with major depression

Method of Use · Assigned to Orexigen Therapeutics Inc · Expires 2032-01-13 · 6y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods for providing weight loss therapy to patients with major depression.

USPTO Abstract

Disclosed are methods of providing weight loss therapy, particularly for patients suffering from major depression.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1808`	—

Patent Metadata

Patent number: US9248123
Jurisdiction: US
Classification: Method of Use
Expires: 2032-01-13
Drug substance claim: No
Drug product claim: No
Assignee: Orexigen Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.